about
From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study.
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Teriflunomide for multiple sclerosis
@ast
Teriflunomide for multiple sclerosis
@en
Teriflunomide for multiple sclerosis
@en-gb
Teriflunomide for multiple sclerosis
@nl
type
label
Teriflunomide for multiple sclerosis
@ast
Teriflunomide for multiple sclerosis
@en
Teriflunomide for multiple sclerosis
@en-gb
Teriflunomide for multiple sclerosis
@nl
prefLabel
Teriflunomide for multiple sclerosis
@ast
Teriflunomide for multiple sclerosis
@en
Teriflunomide for multiple sclerosis
@en-gb
Teriflunomide for multiple sclerosis
@nl
P2093
P2860
P1476
Teriflunomide for multiple sclerosis
@en
P2093
Chao Zhang
Qingqing Dai
Yifan Zhang
P2860
P356
10.1002/14651858.CD009882.PUB3
P577
2016-03-22T00:00:00Z